FAQ SEARCH

CAR T-cell therapy is an advanced immunotherapy in which a patient’s own T cells are genetically modified to better recognize and attack cancer cells, then reinfused back into the body.

It is primarily used for certain blood cancers, including specific types of leukemia and lymphoma. It is FDA-approved and shows high response rates in eligible patients.

Success varies by cancer type, but in some forms of leukemia, response rates can reach up to 90% in eligible patients.

Common side effects may include cytokine release syndrome (fever, fatigue), neurological symptoms, and temporary immune suppression. These are closely monitored by the medical team.

The full process — cell collection, laboratory modification, preparatory treatment, and infusion — typically takes several weeks.

Yes. CAR-T therapy is a new immunotherapy approved by the FDA for relapsed leukemia with remission rates up to 90%.

Patients with relapsed or refractory B-cell ALL, including children, young adults, and adults depending on clinical criteria.

Yes, but it may cause CRS and neurotoxicity, which are manageable with proper monitoring.

Some patients remain cancer-free for 4–6 years based on long-term follow-up of clinical trials.

CAR-T treatment prices vary by center, product, and hospitalization needs. Most FDA-approved CAR-T therapies globally fall within $100,000–$190,000, excluding travel and supportive care.

CAR-T involves cell engineering, personalized manufacturing, and specialized hospital care—making the average price six figures worldwide.

The U.S. remains the most expensive market (up to $450K total package), while European centers offer $100–190K ranges. Türkiye remains competitive with lower facility costs.

When compared to survival rates and long-term remission data, many patients find CAR-T cost justified—especially after relapse post-chemotherapy or transplant.

The final cost depends on cell processing, lymphodepletion chemo, ICU availability, CRS/ICANS management, and length of stay. Typical range: $100–190K.

Many countries partially reimburse CAR-T due to strong clinical outcomes. Some insurers cover up to 70–90% depending on diagnosis.

Emerging centers in Eastern Europe and Türkiye offer high-quality CAR-T programs within the $100K–$190K standard global range, easing financial burden.

The FDA has approved multiple CAR-T therapies for leukemia, lymphoma, and myeloma, marking a major breakthrough in cancer treatment.

Hundreds of clinical trials worldwide are exploring CAR-T therapy for both blood cancers and solid tumors, expanding the treatment potential.

CAR-T cell manufacturing involves leukapheresis, genetic modification, cell expansion, and reinfusion into the patient.

TIL (Tumor-Infiltrating Lymphocyte) therapy is an immunotherapy approach in which a patient’s own immune cells are harvested, expanded in the laboratory, and reinfused to fight cancer.

No. TIL therapy is currently used more commonly in certain solid tumors, especially metastatic melanoma. Suitability is decided upon individual evaluation.

Its personalized nature and ability to strengthen the immune system in a solid-tumor targeted way are its primary advantages over general therapies.

Yes, including fever, fatigue, or temporary immune suppression. These are typically managed under expert medical supervision.

The process, including cell expansion in the lab and preparatory regimens, usually takes 4-6 weeks.

Lifileucel (Amtagvi) received accelerated FDA approval for advanced melanoma. Research continues for other tumor types.

Immunotherapy consists of treatments that stimulate or support the immune system to recognize and destroy cancer cells (e.g., PD-1 inhibitors, CAR-T, TIL).

Targeted therapies are drugs constructed to focus on specific molecular targets (mutations) in cancer cells, sparing normal cells more than chemotherapy.

It identifies DNA characteristics of the tumor to help doctors determine if a patient will benefit from specific targeted or immunotherapies.

Clinical trials test the safety and effectiveness of new treatments. They offer options when standard treatments are limited.

CAR-T cells are genetically engineered blood T-cells, whereas TILs are natural T-cells harvested directly from the tumor and expanded.

They are highly personalized, requiring complex GMP manufacturing, high-tech facilities, and specialized medical teams for a single patient's treatment.

Patients often ask what this price covers:
 – Pre-testing
 – Cell collection
 – Manufacturing
 – Chemotherapy
 – Infusion
 – Hospital monitoring
 – CRS treatment

For refractory leukemia/lymphoma, CAR-T remains the most effective therapy—alternatives rarely match remission rates.

CAR-T therapy is used for B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma, and more.

By engineering T cells to express chimeric antigen receptors that recognize and kill cancer cells.

CAR-T cell manufacturing involves leukapheresis, genetic modification, cell expansion, and reinfusion into the patient.

CAR-T therapy process takes several weeks, from cell collection to infusion, requiring coordination and patient preparation.

Response rates range from 25–44% depending on cancer type, with long-term remission reported.

Side effects mainly stem from IL-2 and conditioning chemotherapy but are manageable in expert centers.

The process usually takes 4–6 weeks from tumor collection to infusion.

Surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell / bone marrow transplant, and supportive/palliative care.

Chemotherapy aims to kill rapidly dividing cancer cells; common side effects include nausea, hair loss, increased infection risk, and anemia

It uses high-energy radiation to damage the DNA of tumor cells, killing them or stopping their growth. It is a localized treatment.

No. Surgery is usually preferred in early-stage or localized cancers where the tumor can be removed. In metastatic or widespread disease, surgery may have limited benefit.

Palliative care focuses on relieving pain and other symptoms and improving quality of life. It can be given alongside life-prolonging treatments.

It identifies DNA or protein characteristics of the tumor to help determine which patients may benefit from targeted therapies or immunotherapies.

Clinical trials test the safety and effectiveness of new treatments. They can offer options when standard treatments are limited, but benefit is not guaranteed.

CAR-T cells are genetically engineered from blood T cells to target specific antigens, whereas TILs are T cells taken directly from the tumor and expanded before being given back to the patient.

Lifileucel (Amtagvi) is a TIL therapy in which tumor-derived T cells are expanded and given as a one-time infusion. It received accelerated FDA approval for advanced melanoma.

Studies supporting its approval reported an objective response rate of around 30%, with some patients experiencing durable, long-lasting responses.

Most side effects are related to pre-infusion chemotherapy and high-dose IL-2, including anemia, fever, low platelets, and neutropenia. Cytokine release syndrome and neurotoxicity are reported less frequently than with CAR-T therapies.

Because they are personalized, require complex manufacturing, high-tech one-time procedures, and specialized facilities, which significantly increase costs.

Typically, patients with good overall health, adequate heart and lung function, and advanced melanoma who have already received certain immunotherapies or targeted therapies. Eligibility varies by center and protocol.

To increase effectiveness, delay resistance, and improve tumor shrinkage by using different mechanisms of action (e.g., immunotherapy plus targeted therapy).

Melanoma, certain types of lung cancer, and MSI-high/MMR-deficient colorectal cancers are among those that tend to respond well, with the range of indications continuing to expand.

They are targeted therapies in which a cytotoxic drug is attached to an antibody that specifically recognizes cancer cells, allowing more selective delivery of treatment.

Management depends on the treatment and may include anti-nausea drugs, growth factors, blood products, steroids, and close monitoring by a multidisciplinary team.

Many early-stage cancers are treated with curative intent, but outcomes depend on cancer biology, treatment type, and patient factors, so cure cannot always be guaranteed.

The goals are usually to control the disease, relieve symptoms, and improve or maintain quality of life. Some patients may experience long-term response.

Adjuvant therapy is given after surgery to reduce the risk of recurrence, while neoadjuvant therapy is given before surgery to shrink the tumor.

If inherited mutations (such as BRCA or Lynch syndrome) are found, both treatment decisions and cancer screening strategies for family members may change.

Treatment is tailored based on comorbidities, functional status, and tolerance, with dose adjustments and enhanced supportive care.

It is often used in some blood cancers after high-dose chemotherapy, but its role is limited in solid tumors.

It refers to microscopic or small remaining cancer cells after treatment, which may require additional therapy or close follow-up.

Palliative care can be introduced from the time of diagnosis if there are symptoms or quality-of-life concerns, and early referral is recommended.

Yes. Immune-related side effects affecting the skin, thyroid, colon, liver, lungs, and other organs can occur later and may require long-term monitoring

Cancer cells can acquire mutations, activate alternative signaling pathways, or lose drug targets, which is why combination therapies and new agents are continuously researched.

NCCN and ASCO guidelines, specialized cancer centers, expert oncologists, and clinical trials are the most up-to-date sources. Referral centers are often recommended.

They may include local tissue stiffening, fibrosis, organ dysfunction, and a small risk of secondary cancers, depending on the radiation area

It helps restore function, manage fatigue, provide psychological support, and improve overall quality of life through a multidisciplinary approach.

It may be less effective if the tumor microenvironment is immunosuppressive, the target antigen is absent, or the patient’s immune system is weak.

No. They can only be used when a specific molecular target or mutation is present, which is why molecular testing is required.

It involves scheduled clinical exams, imaging tests, and sometimes tumor markers, according to cancer-specific guidelines.

Proper nutrition helps manage symptoms, and regular physical activity reduces fatigue and improves quality of life, but plans should be individualized.

Yes. Options such as sperm, egg, or tissue preservation should be discussed before chemotherapy or radiotherapy that may affect reproductive function.

Through clinical trials, molecular-based treatment selection, and combination strategies, usually by consulting specialized oncology centers.

Responses are typically assessed using imaging-based criteria such as RECIST, although immunotherapy can show different response patterns.

Costs vary widely based on drugs, facilities, and production processes. Some new cellular therapies are very expensive, and insurance coverage depends on country and policy.

They are approved through regulatory pathways (such as the FDA) after clinical trials demonstrate safety and effectiveness, sometimes under accelerated approval programs.

It means selecting treatments based on the molecular characteristics of an individual patient’s tumor, often involving targeted drugs and immunotherapies.

Medical oncologists, surgeons, radiation oncologists, nurses, palliative care specialists, dietitians, physical therapists, social workers, and clinical research staff.

It varies greatly depending on cancer type, response to treatment, overall health, and tumor biology, and giving a single number is often misleading.

By following ClinicalTrials.gov, cancer center teams, patient advocacy groups, and guideline-issuing organizations such as ASCO or NCI.

Lack of response, unacceptable side effects, new test results, or patient preferences can all lead to changes in the treatment plan.

On the websites of regulatory agencies such as the FDA and EMA, which publish approval letters, prescribing information, and review documents.

Through neutropenia management, sterile procedures, antiviral/antibiotic protocols, and patient education.

Clinical trials use selected patient groups and strict protocols, whereas real-world data reflect more diverse patient populations and everyday clinical practice.

Expansion of cellular therapies to solid tumors (e.g., TIL approvals), immunotherapy combinations, antibody–drug conjugates, personalized vaccines, and improved biomarker-driven treatment strategies.